Drugs

Papers
(The TQCC of Drugs is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
ArticleCitations
Prevention and Treatment of Monkeypox342
BNT162b2 mRNA COVID-19 Vaccine: First Approval237
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update206
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin198
Pharmaco-Immunomodulatory Therapy in COVID-19196
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences195
Inclisiran: First Approval188
Lumasiran: First Approval178
Remdesivir: First Approval172
Nirmatrelvir Plus Ritonavir: First Approval168
Casimersen: First Approval154
Aducanumab: First Approval137
Acute Pancreatitis: Diagnosis and Treatment132
Sotorasib: First Approval123
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I107
Risdiplam: First Approval105
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update101
TRPV1-Targeted Drugs in Development for Human Pain Conditions101
Setmelanotide: First Approval101
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing97
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis93
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects91
Selpercatinib: First Approval90
Belantamab Mafodotin: First Approval90
Bulevirtide: First Approval89
Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?88
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer84
Orelabrutinib: First Approval84
Inhaled Liposomal Antimicrobial Delivery in Lung Infections82
Nivolumab Plus Relatlimab: First Approval79
REGN-EB3: First Approval77
Amivantamab: First Approval76
Lonafarnib: First Approval75
Fabry Disease: The Current Treatment Landscape74
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety74
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review71
Decitabine/Cedazuridine: First Approval70
Deucravacitinib: First Approval70
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder69
Pralsetinib: First Approval69
Remimazolam: A Review in Procedural Sedation68
Belzutifan: First Approval67
Savolitinib: First Approval66
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases65
Faricimab: First Approval64
Inebilizumab: First Approval64
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations60
Tisotumab Vedotin: First Approval60
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-1960
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections58
Casirivimab/Imdevimab: First Approval58
Disitamab Vedotin: First Approval57
Molnupiravir: First Approval57
Vutrisiran: First Approval57
Abrocitinib: First Approval57
Infigratinib: First Approval55
Telitacicept: First Approval55
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain55
Efgartigimod: First Approval54
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis54
Trilaciclib: First Approval54
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma54
Contezolid: First Approval53
Current Status of Clinical Trials on Tau Immunotherapies53
Targeting AMPK by Statins: A Potential Therapeutic Approach53
Cadonilimab: First Approval52
Tebentafusp: First Approval52
Loncastuximab Tesirine: First Approval51
Dostarlimab: First Approval51
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections50
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals50
Lecanemab: First Approval50
Filgotinib: First Approval49
Pegcetacoplan: First Approval49
Lurbinectedin: First Approval49
Tirzepatide: First Approval48
Umbralisib: First Approval48
Ocrelizumab: A Review in Multiple Sclerosis48
Naxitamab: First Approval47
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective46
Daprodustat: First Approval46
Envafolimab: First Approval46
Odevixibat: First Approval46
Management of Thrombotic Complications in COVID-19: An Update45
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics44
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations44
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review43
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update43
Therapeutic Options in Hereditary Optic Neuropathies43
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents43
Tremelimumab: First Approval43
Anifrolumab: First Approval42
Givosiran: A Review in Acute Hepatic Porphyria42
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics42
Voclosporin: First Approval41
Regdanvimab: First Approval41
Fuzuloparib: First Approval41
Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon41
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs41
Lazertinib: First Approval40
Chronic Pancreatitis: Epidemiology, Diagnosis, and Management Updates40
Mavacamten: First Approval40
Tezepelumab: First Approval40
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review40
Functional Dyspepsia: Diagnostic and Therapeutic Approaches40
Sotrovimab: First Approval39
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists39
Mosunetuzumab: First Approval38
Satralizumab: First Approval38
Nirsevimab: First Approval38
Spesolimab: First Approval38
Teclistamab: First Approval38
Mirvetuximab Soravtansine: First Approval37
Adagrasib: First Approval37
Asciminib: First Approval36
Evinacumab: First Approval36
Pamiparib: First Approval36
Donafenib: First Approval36
Vadadustat: First Approval36
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy36
Tixagevimab + Cilgavimab: First Approval35
Daridorexant: First Approval35
Avacopan: First Approval35
Melphalan Flufenamide (Melflufen): First Approval35
Valoctocogene Roxaparvovec: First Approval35
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?35
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents34
Olverembatinib: First Approval34
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions34
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A34
Vericiguat: First Approval34
Etranacogene Dezaparvovec: First Approval34
Finerenone: First Approval34
Delandistrogene Moxeparvovec: First Approval33
Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?33
Mobocertinib: First Approval33
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes32
Ozoralizumab: First Approval32
Ansuvimab: First Approval32
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study32
Maralixibat: First Approval31
Margetuximab: First Approval31
Ibrexafungerp: First Approval31
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease31
Oliceridine: First Approval31
Androgenetic Alopecia: Therapy Update31
Futibatinib: First Approval31
Atogepant: First Approval31
Tapinarof Cream 1%: First Approval30
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)30
Difelikefalin: First Approval29
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa29
Post-Thoracotomy Pain: Current Strategies for Prevention and Treatment29
Belumosudil: First Approval28
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections28
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis28
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC28
Tofersen: First Approval28
Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry28
Oteseconazole: First Approval27
Hetrombopag: First Approval27
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?27
Lenacapavir: First Approval27
Pacritinib: First Approval26
Enarodustat: First Approval26
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence26
Secukinumab: A Review in Psoriatic Arthritis26
Tralokinumab: First Approval26
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies26
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars25
Nemolizumab: First Approval25
Ganaxolone: First Approval25
Deprescribing Opioids in Chronic Non-cancer Pain: Systematic Review of Randomised Trials25
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets25
Fostemsavir: First Approval25
New Agents in Development for Sepsis: Any Reason for Hope?25
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?25
Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review25
0.65871620178223